Systemic sclerosis |
UVA |
- |
- |
requires evaluation |
|
UVA128–31
|
low-/medium-dose |
E, C |
benefit, especially suited for acrosclerosis and partial body exposure |
|
PUVA18,32–34
|
medium-dose |
E, D |
bath application in childhood discussed |
Localized scleroderma |
UVA36,37
|
low-dose |
C |
benefit, no further evaluation |
|
UVA138–45
|
low-/medium-/high-dose |
D, C |
no exact recommendation in favor to best dosage, benefit, combination with calcipotriol where appropriate, successful in childhood/adolescence |
|
PUVA19,32,34,46–51
|
high-dose |
E, D |
questionable efficacy, extreme variance in dosage, combination (cream) with calcipotriol in childhood |
Extragenital lichen sclerosus et atrophicus |
UVA |
- |
- |
requires evaluation |
|
UVA140,56–58
|
low-dose |
E, D, C |
effectiveness, disputable in combined morphea/lichen sclerosis et atrophicus |
|
PUVA59,60
|
low-dose |
E |
benefit, careful cream therapy for genitoanal lesions where appropriate |
Sclerodermoid graft- vs-host disease |
UVA |
- |
- |
requires evaluation |
|
UVA162–64
|
low-/medium-dose |
E, D |
partial efficacy, medium-dose possibly more effective than low-dose, combined UV/immunosuppressive therapy |
|
PUVA65–71
|
medium-dose |
E, D, C |
skeptical effectiveness, potentially adjunct therapy in addition to conventional chemotherapy, more effective in lichenoid than sclerodermoid lesions |
Lupus erythematosus |
UVA |
- |
- |
requires evaluation |
|
UVA173–78
|
low-dose |
D, C, A |
benefit in occasional cases, long-term application |
|
PUVA |
- |
- |
requires evaluation |